TAO Synergies Inc
NASDAQ:TAOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TAO Synergies Inc
NASDAQ:TAOX
|
US |
|
A
|
Almaden Minerals Ltd
OTC:AAUAF
|
CA |
|
C
|
China New Energy Ltd
HKEX:1156
|
CN |
|
G
|
Grupo Ecoener SA
MAD:ENER
|
ES |
|
Balance Labs Inc
OTC:BLNC
|
US |
|
Fine Organic Industries Ltd
NSE:FINEORG
|
IN |
TAO Synergies Inc
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm's differentiated cryptocurrency treasury strategy is centered exclusively on the acquisition of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI.
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm's differentiated cryptocurrency treasury strategy is centered exclusively on the acquisition of TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI.
